Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Alaunos Therapeutics ( (TCRT) ) is now available.
On June 24, 2025, Alaunos Therapeutics, Inc. entered into a Subscription Agreement to issue and sell Series A-2 Convertible Preferred Stock in a private offering, raising $850,000. The Series A-2 Preferred Stock, with a stated value of $1,000 per share, offers a 10% annual dividend and voting rights on an as-converted basis with common stock. This strategic move may enhance Alaunos Therapeutics’ financial flexibility and influence its market positioning.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Average Trading Volume: 498,521
Technical Sentiment Signal: Sell
Current Market Cap: $7.39M
See more data about TCRT stock on TipRanks’ Stock Analysis page.